Robert J.  Bertolini net worth and biography

Robert Bertolini Biography and Net Worth

Robert J. Bertolini was President and Chief Financial Officer of Bausch & Lomb Incorporated from February 2013 until August 2013 (until its acquisition by Valeant Pharmaceuticals). Previously, Mr. Bertolini served as Executive Vice President and Chief Financial Officer at Schering-Plough Corp. from November 2003 until November 2009 (through its merger with Merck & Co.) with responsibility for tax, accounting and financial asset management. Prior to joining Schering-Plough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, ultimately leading its global pharmaceutical industry practice. Mr. Bertolini also serves as a director of Bristol-Meyers Squibb Company and Idorsia, Ltd., a Swiss public company. He served as a director of Genzyme Corporation until its merger with Sanofi-Aventis in 2011, and Actelion Pharmaceuticals Ltd. until it was acquired. Mr. Bertolini has been a director since January 2011.

What is Robert J. Bertolini's net worth?

The estimated net worth of Robert J. Bertolini is at least $8.80 million as of May 20th, 2020. Mr. Bertolini owns 32,664 shares of Charles River Laboratories International stock worth more than $8,798,702 as of March 28th. This net worth estimate does not reflect any other investments that Mr. Bertolini may own. Learn More about Robert J. Bertolini's net worth.

How do I contact Robert J. Bertolini?

The corporate mailing address for Mr. Bertolini and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on Robert J. Bertolini's contact information.

Has Robert J. Bertolini been buying or selling shares of Charles River Laboratories International?

Robert J. Bertolini has not been actively trading shares of Charles River Laboratories International within the last three months. Most recently, Robert J. Bertolini sold 3,530 shares of the business's stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $174.58, for a transaction totalling $616,267.40. Following the completion of the sale, the director now directly owns 32,664 shares of the company's stock, valued at $5,702,481.12. Learn More on Robert J. Bertolini's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, Charles River Laboratories International insiders bought shares 3 times. They purchased a total of 7,942 shares worth more than $1,447,729.04. During the last year, insiders at the medical research company sold shares 7 times. They sold a total of 23,211 shares worth more than $5,481,396.41. The most recent insider tranaction occured on February, 29th when EVP Victoria L Creamer sold 5,000 shares worth more than $1,268,500.00. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 2/29/2024.

Robert J. Bertolini Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2020Sell3,530$174.58$616,267.4032,664View SEC Filing Icon  
2/13/2020Sell7,170$170.41$1,221,839.7031,905View SEC Filing Icon  
12/4/2018Sell3,440$133.77$460,168.8029,876View SEC Filing Icon  
1/2/2018Sell3,609$110.22$397,783.98View SEC Filing Icon  
3/1/2017Sell5,255$87.53$459,970.1532,140View SEC Filing Icon  
See Full Table

Robert J. Bertolini Buying and Selling Activity at Charles River Laboratories International

This chart shows Robert J Bertolini's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $270.95
Low: $267.23
High: $272.19

50 Day Range

MA: $242.91
Low: $206.11
High: $273.43

2 Week Range

Now: $270.95
Low: $161.65
High: $275.00

Volume

496,968 shs

Average Volume

567,239 shs

Market Capitalization

$13.90 billion

P/E Ratio

29.42

Dividend Yield

N/A

Beta

1.39